Slow Capital Inc. Purchases 4,012 Shares of BioNTech SE (NASDAQ:BNTX)

Slow Capital Inc. lifted its position in shares of BioNTech SE (NASDAQ:BNTX) by 15.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,526 shares of the company’s stock after purchasing an additional 4,012 shares during the period. Slow Capital Inc.’s holdings in BioNTech were worth $3,116,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in BNTX. Eagle Bay Advisors LLC bought a new position in BioNTech during the 2nd quarter worth $33,000. State of Wyoming bought a new position in BioNTech during the second quarter worth about $26,000. Covestor Ltd acquired a new stake in BioNTech in the 3rd quarter worth about $32,000. Resurgent Financial Advisors LLC acquired a new stake in BioNTech in the 4th quarter worth about $47,000. Finally, UMB Bank n.a. bought a new stake in BioNTech in the 4th quarter valued at about $50,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BNTX shares. Oppenheimer began coverage on shares of BioNTech in a research report on Friday, January 5th. They issued a “market perform” rating for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a report on Thursday, March 21st. HC Wainwright cut their target price on BioNTech from $133.00 to $107.00 and set a “buy” rating for the company in a research report on Tuesday, January 23rd. JPMorgan Chase & Co. decreased their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research report on Friday, March 22nd. Finally, The Goldman Sachs Group cut their price objective on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $120.40.

BioNTech Price Performance

Shares of BNTX stock traded down $0.46 on Wednesday, hitting $85.88. 411,611 shares of the company’s stock were exchanged, compared to its average volume of 659,572. The company has a 50 day moving average of $91.67 and a 200 day moving average of $97.64. The stock has a market cap of $20.42 billion, a P/E ratio of 20.77 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. BioNTech SE has a 12 month low of $85.21 and a 12 month high of $125.83.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. On average, equities research analysts predict that BioNTech SE will post -1.67 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.